PARSIPPANY, N.J., April 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its first quarter 2012 financial results on Monday, April 30, 2012 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on April 30, 2012 to discuss its financial results and provide an update on the Company's outlook for 2012. The dial-in number to access the call is US/Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 73123257.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Time on May 14, 2012. The replay may be accessed by dialing (855) 859-2056 and entering pass code 73123257. From international locations, the replay may be accessed by dialing (404) 537-3406 and entering the same pass code. To access the webcast, go to Watson's Investor Relations Web site at http://ir.watson.com. A replay of the webcast will also be available.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )


    CONTACTS:                         Investors:
                                      Patty Eisenhaur
                                      (862) 261-8141

                                      Media:
                                      Charlie Mayr
                                      (862) 261-8030

SOURCE Watson Pharmaceuticals, Inc.